Familial Chylomicronemia (Type I Hyperlipoproteinemia) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Familial Chylomicronemia (Type I Hyperlipoproteinemia) – Drugs In Development, 2024 report and make more profitable business decisions.
Familial chylomicronemia syndrome (hyperlipoproteinemia type 1) is an inherited condition that disrupts the breakdown of fats in the body, causing high levels of fat to build up in the blood. It is characterized by pancreatitis, abdominal pain, enlargement of the liver and spleen (hepatosplenomegaly), and small yellow skin lesions called eruptive xanthomas. Familial chylomicronemia syndrome is caused by genetic changes in the LPL gene that are inherited in an autosomal recessive pattern.
The Familial Chylomicronemia (Type I Hyperlipoproteinemia) drugs in development market research report provide comprehensive information on the therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Familial Chylomicronemia (Type I Hyperlipoproteinemia) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Familial Chylomicronemia (Type I Hyperlipoproteinemia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Familial Chylomicronemia (Type I Hyperlipoproteinemia) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Arrowhead Pharmaceuticals IncChiesi Farmaceutici SpA
iMetabolic Biopharma Corp
Ionis Pharmaceuticals Inc
Lipigon Pharmaceuticals AB
NorthSea Therapeutics BV
Table of Contents
Table
Figures
Frequently asked questions